Veradigm (MDRX) Q4 2024 earnings summary

Executive summary

• Reviewed audited 2022 and unaudited 2023–2024 results, with 2025 outlook for flat revenue and net cash positivity; 2023 revenue estimated at $620–$625M, net income $62–$65M, adjusted EBITDA $139–$144M; 2024 revenue $583–$588M, net loss $46–$49M, adjusted EBITDA $85–$90M.

• Completed 2022 restatement, filed Form 10-K with restatements for 2020–2022, and outlined remediation plans for internal control deficiencies.

• Added four new independent directors and refreshed board leadership to enhance oversight.

• Management focused on remediating internal controls, relisting common stock, and executing growth strategy.

Financial highlights

• 2023 GAAP revenue: $620–$625M (includes $19M customer settlements); 2024: $583–$588M (includes $1M settlements); recurring revenue ~80%.

• 2023 adjusted EBITDA: $139–$144M; 2024: $85–$90M; net cash $239M at 2023 year-end, $87M at 2024 year-end, reflecting outflows for acquisitions and expenses.

• Provider segment revenue: $490–$493M (2023), $466–$469M (2024); Payer & Life Science: $130–$132M (2023), $117–$119M (2024).

• CapEx: $30M (2023), $35M (2024); major 2024 outflows for acquisitions ($110M) and transaction/other expenses ($103M).

Outlook and guidance

• 2025 revenue expected to be flat versus 2024, with growth from new contracts and price increases offset by attrition.

• Net cash positive position anticipated through 2025; pursuing additional debt financing for liquidity.

• No specific 2025 profitability guidance; cost realignment underway, with margin improvement expected in 2025 and more in 2026.